-
1دورية أكاديمية
المؤلفون: Tate SC; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK. tate_sonya@lilly.com., Sykes AK; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK., Kulanthaivel P; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA., Chan EM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA., Turner PK; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA., Cronier DM; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2018 Mar; Vol. 57 (3), pp. 335-344.
نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE
مواضيع طبية MeSH: Models, Biological*, Aminopyridines/*administration & dosage , Antineoplastic Agents/*administration & dosage , Benzimidazoles/*administration & dosage , Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Aminopyridines/pharmacokinetics ; Aminopyridines/pharmacology ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Benzimidazoles/pharmacokinetics ; Benzimidazoles/pharmacology ; Biological Availability ; Body Weight ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/pathology ; Sex Factors ; Young Adult
-
2دورية أكاديمية
المؤلفون: Michael M; Division of Cancer Medicine, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia. Michael.Michael@petermac.org., Bang YJ; Seoul National University College of Medicine, Seoul, South Korea., Park YS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Kim TM; Seoul National University Hospital, Seoul, South Korea., Hamid O; Eli Lilly and Company, Indianapolis, IN, USA., Thornton D; Eli Lilly and Company, Indianapolis, IN, USA., Tate SC; Eli Lilly and Company, Basingstoke, Hampshire, UK., Raddad E; Eli Lilly and Company, Indianapolis, IN, USA., Tie J; Division of Cancer Medicine, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Royal Melbourne Hospital, Melbourne, Australia.
المصدر: Targeted oncology [Target Oncol] 2017 Aug; Vol. 12 (4), pp. 463-474.
نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung/*drug therapy , Indazoles/*administration & dosage , Lung Neoplasms/*drug therapy , Receptors, Fibroblast Growth Factor/*antagonists & inhibitors , Stomach Neoplasms/*drug therapy, Administration, Oral ; Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/metabolism ; Cohort Studies ; Dose-Response Relationship, Drug ; Female ; Humans ; Indazoles/adverse effects ; Indazoles/pharmacokinetics ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Stomach Neoplasms/metabolism ; Young Adult
-
3دورية أكاديمية
المؤلفون: Tate SC; PK/PD, Eli Lilly and Company, Erl Wood Manor, Windlesham, GU20 6PH, UK. Electronic address: tate_sonya@network.lilly.com., Andre V; Statistics, Eli Lilly and Company, Erl Wood Manor, Windlesham, GU20 6PH, UK. Electronic address: andre_valerie@lilly.com., Enas N; Statistics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: enas_nathan_h@lilly.com., Ribba B; Project-Team NuMed, INRIA, Ecole Normale Supérieure de Lyon, Lyon, France. Electronic address: benjamin.ribba@inria.fr., Gueorguieva I; PK/PD, Eli Lilly and Company, Erl Wood Manor, Windlesham, GU20 6PH, UK. Electronic address: gueorguieva_ivelina@lilly.com.
المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2016 Oct; Vol. 66, pp. 95-103. Date of Electronic Publication: 2016 Aug 18.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*pathology, Breast Neoplasms/drug therapy ; Breast Neoplasms/mortality ; Capecitabine/administration & dosage ; Clinical Trials, Phase III as Topic ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Docetaxel ; Female ; Humans ; Neoplasm Metastasis ; Paclitaxel/administration & dosage ; Prognosis ; Randomized Controlled Trials as Topic ; Taxoids/administration & dosage ; Tumor Burden/drug effects ; Gemcitabine
-
4دورية أكاديمية
المؤلفون: Tate SC; Global PK/PD, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK., Burke TF; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Hartman D; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Kulanthaivel P; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Beckmann RP; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Cronier DM; Global PK/PD, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
المصدر: British journal of cancer [Br J Cancer] 2016 Mar 15; Vol. 114 (6), pp. 669-79.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Melanoma/*drug therapy, Aminopyridines/administration & dosage ; Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Benzimidazoles/administration & dosage ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Humans ; Indoles/administration & dosage ; Indoles/pharmacokinetics ; Melanoma/enzymology ; Melanoma/genetics ; Melanoma/metabolism ; Mice ; Models, Biological ; Mutation ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/metabolism ; Sulfonamides/administration & dosage ; Sulfonamides/pharmacokinetics ; Vemurafenib ; Xenograft Model Antitumor Assays
-
5دورية أكاديمية
المؤلفون: Tate SC; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and tate_sonya@network.lilly.com., Cai S; Eli Lilly and Company, Indianapolis, Indiana., Ajamie RT; Eli Lilly and Company, Indianapolis, Indiana., Burke T; Eli Lilly and Company, Indianapolis, Indiana., Beckmann RP; Eli Lilly and Company, Indianapolis, Indiana., Chan EM; Eli Lilly and Company, Indianapolis, Indiana., De Dios A; Eli Lilly and Company, Indianapolis, Indiana., Wishart GN; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and., Gelbert LM; Eli Lilly and Company, Indianapolis, Indiana., Cronier DM; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and.
المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Jul 15; Vol. 20 (14), pp. 3763-74. Date of Electronic Publication: 2014 May 21.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
مواضيع طبية MeSH: Aminopyridines/*pharmacokinetics , Antineoplastic Agents/*pharmacokinetics , Benzimidazoles/*pharmacokinetics, Administration, Oral ; Aminopyridines/therapeutic use ; Animals ; Antineoplastic Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Humans ; Inhibitory Concentration 50 ; Mice, Nude ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/therapeutic use ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays
-
6دورية أكاديمية
المؤلفون: Jones HM; Pfizer Worldwide R&D, Department of Pharmacokinetics, Dynamics and Metabolism, Sandwich, Kent, United Kingdom. hannah.jones@pfizer.com, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS
المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2012 May; Vol. 40 (5), pp. 1007-17. Date of Electronic Publication: 2012 Feb 16.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE
مواضيع طبية MeSH: Models, Biological* , Pharmacokinetics*, Drug Discovery/*methods , Hepatocytes/*metabolism , Organic Anion Transporters/*metabolism , Pharmaceutical Preparations/*metabolism, Cell Culture Techniques ; Cells, Cultured ; Chemistry, Physical ; Chromatography, High Pressure Liquid ; Computer Simulation ; Cryopreservation ; Hepatocytes/cytology ; Humans ; Injections, Intravenous ; Organ Specificity ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/chemistry ; Predictive Value of Tests ; Substrate Specificity ; Tissue Distribution